Literature DB >> 21337516

Tandem application of cationic colloidal silica and Triton X-114 for plasma membrane protein isolation and purification: towards developing an MDCK protein database.

Rommel A Mathias1, Yuan-Shou Chen, Robert J A Goode, Eugene A Kapp, Suresh Mathivanan, Robert L Moritz, Hong-Jian Zhu, Richard J Simpson.   

Abstract

Plasma membrane (PM) proteins are attractive therapeutic targets because of their accessibility to drugs. Although genes encoding PM proteins represent 20-30% of eukaryotic genomes, a detailed characterisation of their encoded proteins is underrepresented, due, to their low copy number and the inherent difficulties in their isolation and purification as a consequence of their high hydrophobicity. We describe here a strategy that combines two orthogonal methods to isolate and purify PM proteins from Madin Darby canine kidney (MDCK) cells. In this two-step method, we first used cationic colloidal silica (CCS) to isolate adherent (Ad) and non-adherent (nAd) PM fractions, and then subjected each fraction to Triton X-114 (TX-114) phase partitioning to further enrich for hydrophobic proteins. While CCS alone identified 255/757 (34%) membrane proteins, CCS/TX-114 in combination yielded 453/745 (61%). Strikingly, of those proteins unique to CCS/TX-114, 277/393 (70%) had membrane annotation. Further characterisation of the CCS/TX-114 data set using Uniprot and transmembrane hidden Markov model revealed that 306/745 (41%) contained one or more transmembrane domains (TMDs), including proteins with 25 and 17 TMDs. Of the remaining proteins in the data set, 69/439 (16%) are known to contain lipid modifications. Of all membrane proteins identified, 93 had PM origin, including proteins that mediate cell adhesion, modulate transmembrane ion transport, and cell-cell communication. These studies reveal that the application of CCS to first isolate Ad and nAd PM fractions, followed by their detergent-phase TX-114 partitioning, to be a powerful method to isolate low-abundance PM proteins, and a useful adjunct for in-depth cell surface proteome analyses.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21337516     DOI: 10.1002/pmic.201000591

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

1.  An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis.

Authors:  Piia-Riitta Karhemo; Suvi Ravela; Marko Laakso; Ilja Ritamo; Olga Tatti; Selina Mäkinen; Steve Goodison; Ulf-Håkan Stenman; Erkki Hölttä; Sampsa Hautaniemi; Leena Valmu; Kaisa Lehti; Pirjo Laakkonen
Journal:  J Proteomics       Date:  2012-07-17       Impact factor: 4.044

2.  Nanowire pellicles for eukaryotic cells: nanowire coating and interaction with cells.

Authors:  Sung-Kyoung Kim; Waeowalee Choksawangkarn; Rebecca Rose; Catherine Fenselau; Sang Bok Lee
Journal:  Nanomedicine (Lond)       Date:  2013-07-31       Impact factor: 5.307

3.  Analysis of lipid-composition changes in plasma membrane microdomains.

Authors:  Hideo Ogiso; Makoto Taniguchi; Toshiro Okazaki
Journal:  J Lipid Res       Date:  2015-06-26       Impact factor: 5.922

4.  Enrichment of plasma membrane proteins using nanoparticle pellicles: comparison between silica and higher density nanoparticles.

Authors:  Waeowalee Choksawangkarn; Sung-Kyoung Kim; Joe R Cannon; Nathan J Edwards; Sang Bok Lee; Catherine Fenselau
Journal:  J Proteome Res       Date:  2013-01-31       Impact factor: 4.466

5.  Metastasis-associated cell surface oncoproteomics.

Authors:  Piia-Riitta Karhemo; Maija Hyvönen; Pirjo Laakkonen
Journal:  Front Pharmacol       Date:  2012-11-07       Impact factor: 5.810

6.  Quantitative proteomics of MDCK cells identify unrecognized roles of clathrin adaptor AP-1 in polarized distribution of surface proteins.

Authors:  Paulo S Caceres; Diego Gravotta; Patrick J Zager; Noah Dephoure; Enrique Rodriguez-Boulan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-29       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.